

Guan Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7854617/publications.pdf>

Version: 2024-02-01

31
papers

1,014
citations

394421

19
h-index

454955

30
g-index

33
all docs

33
docs citations

33
times ranked

1580
citing authors

#	ARTICLE	IF	CITATIONS
1	Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance. <i>Experimental Hematology</i> , 2022, 105, 39-49.	0.4	10
2	Identifying a Novel Critical Access Difficulty Factor in Percutaneous Radiofrequency Rhizotomy for Trigeminal Neuralgia: Pterygoid Process Ridge. <i>Operative Neurosurgery</i> , 2022, Publish Ahead of Print, .	0.8	2
3	Venetoclax enhances DNA damage induced by XPO1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 2646-2657.	3.6	9
4	The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia. <i>Haematologica</i> , 2021, 106, 1262-1277.	3.5	24
5	Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 415-423.	2.3	7
6	BiVO ₄ /Fe ₃ O ₄ @polydopamine superparticles for tumor multimodal imaging and synergistic therapy. <i>Journal of Nanobiotechnology</i> , 2021, 19, 90.	9.1	16
7	The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML. <i>Blood Cancer Journal</i> , 2021, 11, 111.	6.2	22
8	Polysaccharides Extracted From Panax Ginseng C.A. Mey Enhance Complement Component 4 Biosynthesis in Human Hepatocytes. <i>Frontiers in Pharmacology</i> , 2021, 12, 734394.	3.5	2
9	Optical coherence tomography-guided drug coated balloon in non-small de novo coronary artery lesions: a prospective clinical research. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 11617-11624.	0.0	0
10	Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation. <i>Cancers</i> , 2020, 12, 2400.	3.7	26
11	CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 7239-7253.	3.6	35
12	Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2019, 25, 6815-6826.	7.0	115
13	Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo. <i>Targeted Oncology</i> , 2019, 14, 351-364.	3.6	5
14	Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 2225-2240.	3.5	53
15	Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. <i>Biochemical Pharmacology</i> , 2018, 148, 13-26.	4.4	38
16	Resveratrol Prevents Diabetic Cardiomyopathy by Increasing Nrf2 Expression and Transcriptional Activity. <i>BioMed Research International</i> , 2018, 2018, 1-13.	1.9	39
17	Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells. <i>Scientific Reports</i> , 2017, 7, 41950.	3.3	42
18	Immobilization of β -2-Cyclodextrin-Conjugated Lactoferrin onto Polymer Monolith for Enrichment of Ga in Metabolic Residues of Ga-Based Anticancer Drugs. <i>Biomacromolecules</i> , 2017, 18, 3971-3977.	5.4	7

#	ARTICLE	IF	CITATIONS
19	Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 44295-44311.	1.8	29
20	Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. <i>Clinical Cancer Research</i> , 2016, 22, 4440-4451.	7.0	176
21	miR-148b-3p inhibits malignant biological behaviors of human glioma cells induced by high HOTAIR expression. <i>Oncology Letters</i> , 2016, 12, 879-886.	1.8	45
22	Down-regulation of microRNA-320 suppresses cardiomyocyte apoptosis and protects against myocardial ischemia and reperfusion injury by targeting IGF-1. <i>Oncotarget</i> , 2016, 7, 39740-39757.	1.8	65
23	Anti-Apoptotic Effect of MicroRNA-30b in Early Phase of Rat Myocardial Ischemia-Reperfusion Injury Model. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 2610-2619.	2.6	20
24	Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. <i>Molecular Oncology</i> , 2015, 9, 409-421.	4.6	35
25	Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer. <i>Cancer Letters</i> , 2015, 356, 656-668.	7.2	32
26	Study of Novel Coating Strategy: Simultaneous Coating of VEGF and anti-CD34 Antibody. <i>Brazilian Journal of Cardiovascular Surgery</i> , 2015, 30, 159-63.	0.6	3
27	The Protective Effect of MicroRNA-320 on Left Ventricular Remodeling after Myocardial Ischemia-Reperfusion Injury in the Rat Model. <i>International Journal of Molecular Sciences</i> , 2014, 15, 17442-17456.	4.1	58
28	Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. <i>Cancer Letters</i> , 2014, 348, 20-28.	7.2	24
29	Cellular Mechanisms of a New Pyrazinone Compound that Induces Apoptosis in SKOV-3 Cells. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 797-802.	1.2	2
30	Panobinostat Synergistically Enhances the Cytotoxic Effects of Cisplatin, Doxorubicin or Etoposide on High-Risk Neuroblastoma Cells. <i>PLoS ONE</i> , 2013, 8, e76662.	2.5	32
31	Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer. <i>PLoS ONE</i> , 2012, 7, e52095.	2.5	41